RxDoctor Payments Data

Glen Smith, MD

Family Medicine · Orange, CANPI 1912096579

Payments from drug & device makers

$478in general payments, 2019–2025

Across 26 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$80
  • Pfizer$59
  • Amgen$58
  • GSK$52
  • Astellas Pharma US Inc$38
  • Merck$26
  • plus $166 from 9 others

What the payments were for

  • Consulting fees$122%
  • Food & beverage$46698%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$478 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$47,911
Medicare patients
99
Services billed
3,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin43$69,517
EliquisApixaban60$61,626
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$34,039
JanuviaSitagliptin Phosphate27$33,663
OzempicSemaglutide20$29,174
FarxigaDapagliflozin Propanediol25$27,702
TradjentaLinagliptin14$16,836
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$10,957
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$7,858
Fentanyl54$6,392
Humalog Kwikpen U-100Insulin Lispro17$3,991
Losartan Potassium324$3,635
Levothyroxine Sodium233$3,538
Famotidine253$3,202
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$3,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$13$86,35357 claims
PfizerEliquis$59$61,62660 claims
GSKTrelegy Ellipta, Anoro Ellipta$52$44,99642 claims
MerckJanuvia$26$33,66327 claims
Novo NordiskOzempic$22$29,17420 claims
AstraZenecaFarxiga$80$27,70225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →